Ea, V.; Berthozat, C.; Dreyfus, H.; Legrand, C.; Rousselet, E.; Peysselon, M.; Baudet, L.; Martinez, G.; Coutton, C.; Bidart, M.
BRCA1 Intragenic Duplication Combined with a Likely Pathogenic TP53 Variant in a Patient with Triple-Negative Breast Cancer: Clinical Risk and Management. Int. J. Mol. Sci. 2024, 25, 6274.
https://doi.org/10.3390/ijms25116274
AMA Style
Ea V, Berthozat C, Dreyfus H, Legrand C, Rousselet E, Peysselon M, Baudet L, Martinez G, Coutton C, Bidart M.
BRCA1 Intragenic Duplication Combined with a Likely Pathogenic TP53 Variant in a Patient with Triple-Negative Breast Cancer: Clinical Risk and Management. International Journal of Molecular Sciences. 2024; 25(11):6274.
https://doi.org/10.3390/ijms25116274
Chicago/Turabian Style
Ea, Vuthy, Claudine Berthozat, Hélène Dreyfus, Clémentine Legrand, Estelle Rousselet, Magalie Peysselon, Laura Baudet, Guillaume Martinez, Charles Coutton, and Marie Bidart.
2024. "BRCA1 Intragenic Duplication Combined with a Likely Pathogenic TP53 Variant in a Patient with Triple-Negative Breast Cancer: Clinical Risk and Management" International Journal of Molecular Sciences 25, no. 11: 6274.
https://doi.org/10.3390/ijms25116274
APA Style
Ea, V., Berthozat, C., Dreyfus, H., Legrand, C., Rousselet, E., Peysselon, M., Baudet, L., Martinez, G., Coutton, C., & Bidart, M.
(2024). BRCA1 Intragenic Duplication Combined with a Likely Pathogenic TP53 Variant in a Patient with Triple-Negative Breast Cancer: Clinical Risk and Management. International Journal of Molecular Sciences, 25(11), 6274.
https://doi.org/10.3390/ijms25116274
